Four months on Wegovy with no weight loss — what might be happening

You're four months in and the number hasn't changed, here's the picture honestly

Picture this: you've been injecting weekly, you've been doing what you were told, and you're watching friends talk about dropping dress sizes. Your four-month weigh-in looks almost identical to your starting weight. That gap between expectation and reality is genuinely frustrating, and it deserves a proper answer rather than reassurance that doesn't hold up.

First, some useful context from the trial data. The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and reported an average body-weight reduction of around 15% at the highest maintenance dose of 2.4mg. The word "average" is doing a lot of work there. A proportion of participants lost significantly less, some lost very little at all. Clinical response to semaglutide is not uniform, and four months is often still the titration period for many patients. If you started at 0.25mg and have been working up in four-weekly steps, you may only recently have reached 1mg or 1.7mg rather than the 2.4mg maintenance dose. The medicine's appetite-suppressing effect tends to be dose-dependent, so comparing your four-month result to someone who has been at full dose for six months is comparing different things. You can read more about what typical progress looks like in our overview of three months on Wegovy.

The NHS guidance on weight-management injections notes that individual response varies and that clinical review is part of ongoing treatment. A prescriber is the right person to assess whether your current dose and approach make sense.

Six things that can genuinely suppress your response to semaglutide

When Wegovy weight loss at four months is minimal, there are usually concrete reasons rather than the medicine simply failing. The most common ones are worth knowing.

Dose still climbing. The titration schedule takes time. At 0.25mg the medicine is settling your system, not yet working at therapeutic intensity. Many people do not reach 2.4mg until around month five or later, especially if a dose increase was paused because of nausea or other side effects.

GI side effects changing eating patterns in unexpected ways. Some people feel nauseated and cut back calories sharply early on, then adapt and gradually return to previous habits without realising it. The appetite signal can plateau between dose increases.

Energy intake higher than perceived. Semaglutide reduces appetite, but liquid calories, alcohol and highly processed foods can offset that reduction significantly. A food diary (even for a fortnight) can reveal patterns that are otherwise invisible.

Sleep and stress. Chronically poor sleep elevates cortisol and ghrelin (a hunger hormone), which can partially counteract the medicine's effect. This is not a character flaw; it is physiology.

Underlying thyroid or metabolic conditions. Untreated or under-treated hypothyroidism, in particular, can blunt weight loss substantially. If this hasn't been checked recently, it is worth raising with your GP.

Individual pharmacokinetics. The rate at which semaglutide is absorbed and cleared differs between people. This is not something that changes with effort; it is simply biology, and it affects response timing. For a fuller breakdown of what to expect across a longer timeline, six months on Wegovy covers the evidence at that later point.

When the NICE guidance says to reconsider treatment, and what that means in practice

It is worth knowing what the formal clinical threshold actually says. NICE's technology appraisal for Wegovy (TA875) recommends reviewing continuation if a patient has lost less than 5% of their body weight after six months on the maintenance dose. Note: six months at maintenance, not six months from starting. If you are four months in and still titrating, you have not yet reached the point where that threshold formally applies.

That said, four months without any movement at all (particularly if you have been at 1.7mg or 2.4mg for most of that time) is a reasonable point to raise with your prescriber. They may want to check for the factors above, review your dose history, consider whether a medicine interaction could be relevant, or discuss whether continuing is the right call. What they should not do is simply extend the prescription without engaging with the question. That is precisely why every repeat at nume involves a fresh clinical review before dispensing, rather than an automatic renewal.

If cost is also on your mind while you work through whether treatment is producing results, our Wegovy pricing page sets out what a legitimate private prescription includes and why the price range across providers varies.

What to do right now if you're in this situation

Start by writing down your dose history: when you started each new strength and whether any increases were delayed. Then consider whether any of the six factors above apply, honestly. Take that list to your prescriber or contact your current provider's clinical aftercare team. If you ordered through an online pharmacy, they should have a direct clinical contact, not just a generic customer service inbox. (December orders being delayed to January, payday cycles affecting when repeat orders go in, these gaps in supply can mean an unintended dose pause that sets back your response timeline more than people realise.)

If you are not currently in any clinical review process and want a fresh assessment, starting a free consultation is the right move. A prescriber can look at your full history, not just the scales. The Wegovy treatment page has further detail on how the medicine works and what clinical monitoring looks like in practice. And if your experience at the two-month mark was already pointing this way, the two-month progress page covers the earlier picture, alongside broader Reuters reporting on Wegovy that puts the medicine's real-world results in wider context.